Key result
Nonalcoholic fatty liver disease increases the risk of atherosclerotic cardiovascular diseases, highlighting the potential of novel antidiabetic and lipid-lowering agents to reduce cardiovascular risk.
Why the study?
Do novel antidiabetic and lipid-lowering agents improve NAFLD and reduce ASCVD risk in patients with NAFLD?
Population
Patients with nonalcoholic fatty liver disease at risk for atherosclerotic cardiovascular diseases
Design
Review
Authors
Loading...
NAFLD warrants attention in ASCVD risk assessment; leaves open whether novel agents improve outcomes.
Do novel antidiabetic and lipid-lowering agents improve NAFLD and reduce ASCVD risk in patients with NAFLD?
NAFLD is a significant risk enhancer for ASCVD, and targeting it with novel antidiabetic and lipid-lowering therapies may reduce cardiovascular risk.
Lefer et al. (1993) conducted a review in Nonalcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular diseases (ASCVD). Nonalcoholic fatty liver disease (NAFLD) was evaluated. Nonalcoholic fatty liver disease increases the risk of atherosclerotic cardiovascular diseases, highlighting the potential of novel antidiabetic and lipid-lowering agents to reduce cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: